Real-World study tests fruquintinib for Tough-to-Treat colorectal cancer
NCT ID NCT06787105
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is observing how well the drug fruquintinib works for people with metastatic colorectal cancer who have already tried standard treatments. About 150 participants in Germany will be treated as part of their normal care, and researchers will track tumor response, survival, side effects, and quality of life. The goal is to see if fruquintinib helps control the disease in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fruquintinib
What this could lead to
If successful, this study could confirm that fruquintinib works well in everyday clinical practice for patients with advanced colorectal cancer who have run out of other options.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also limited to 150 patients in Germany, so findings may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Onkologische Schwerpunktpraxis
RECRUITINGHanover, Lower Saxony, 30161, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact